Antioxidant agent Probucol beneficial influence on incidence and severity of coronary artery restenosis after transluminal balloon coronary angioplasty

Aim. To study perspectives of reducing incidence and severity of coronary artery (CA) restenosis by adding a low dose of antioxidant agent Probucol (250 mg/d) to the treatment before and after transluminal balloon coronary angioplasty (TBCA). Material and methods. The study included 81 patients (mean age 55±6,5 years in Probukol group; 53±6 years in control group; total cholesterol (TCH) level – 6,2±0,66 mmol/l and 6,77±0,79 mmol/l, respectively) with chronic coronary heart disease (CHD), who underwent TBCA and coronaroangiography (CAG) 6 months later. The angiograms were assessed by quantitative computer analysis. Results. In atherosclerosis patients, antioxidant agent Probucol was highly effective not only in the lipid-lowering dose (1000 mg/d), but also in a four-fold reduced dose (250 mg/d). After six-month Probucol treatment (250 mg/d), restenosis incidence was just 19%, comparing to 28% in the control group. In Probucol group, minimal CA lumen diameter was significantly greater, and CA stenosis severity – significantly lower than in control group. Conclusion. The results obtained proved the possibility to reduce restenosis severity by Probucol treatment, even in low dose (250 mg/d), without affecting lipid profile.

1. Зенков Н.К., Кандалинцева Н.В., Ланкин В.З. и др. Фенольные биоантиоксиданты. Новосибирск. Изд-во СО РАМН 2003; 328 с.

2. Зенков Н.К., Ланкин В.З., Меньщикова Е.Б. Окислительный стресс. Биохимический и патофизиологические аспекты. Москва, МАИК “НаукаИнтерпериодика” 2001; 343 с.

3. Ланкин В.З., Тихазе А.К., Беленков Ю.Н. Свободнорадикальные процессы в норме и при заболевания сердечно-сосудистой системы. Кардиология 2000; 40(7): 48-61.

4. Brown BG, Albers JJ, Fisher LD, et al. Regression coronary artery disease as a result of intensive lipid - lowering therapy in men with levels of apolipoproteins B. N Engl J Med 1990; 323: 1289-98.

5. Gruentzig AR, King SB 3rd, Schlumpf M, Siegenthaler W. Long-term follow-up after percutaneous transluminal coronary angioplasty. The early Zurich experience. N Engl J Med 1987; 316(18): 1127-32.

6. Hansson G, Malmsten C, Radmark O. In: Prostaglandins and related substances. Amsterdam-New York-Oxford. Elsevier 1983; 127-69.

7. Clowes AW, Reidy MA. Prevention of stenosis after vascular reconstruction: pharmacologic control of intimal hyperplasia--a review. J Vasc Surg 1991; 13(6): 885-91.

8. Nourooz-Zadeh J, Tajaddini-Sarmadi J, Wolff S.P. Measurement of concentration by the Ferrous oxidation - xylenol orange assay in cojunction with triphenylphosphine. Analyt Biochem 1994; 220: 403-9.

9. Rogers C, Edelman ER, Simon DI. A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci U S A 1998; 95(17): 10134-9.

10. Tanaka K, Hayashi K, Shingu T, et al. Probucol inhibits neointimal formation in carotid arteries of normocholesterolemic rabbits and the proliferation of cultured rabbit vascular smooth muscle cells. Cardiovasc Drugs Ther 1998; 12: 19-28.

11. Tardif JC, Cote G, Lesperanse J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Circulation 1998; 97: 429-36.

12. Yokoi H, Daida H, Kuwabara Y, et al. Effectivness of antioxidans in preventing restenosis after percutaneus transluminal coranary angioplasty: The probucol angioplasty restenosis Trial. JASS 1997; 30: 855-62.